Table 1.
Characteristic of the survey population by group
| Group A | Group B | |
| N (Men/Women) | 57 (43/14) | 59 (39/20) |
| Age (yr.) | 69 (58–74) | 70 (57–76) |
| Duration of disease (yr) | 19 (10–26) | 19 (10–28) |
| Diabetes complications n (%) | ||
| Diabetic retinopathy | 35 (61) | 33 (56) |
| Diabetic neuropathy | 44 (77) | 47 (80) |
| Diabetic nephropathy | 26 (46) | 33 (56) |
| Diabetes Treatment n (%) | ||
| Oral agents | 18 (32) | 20 (34) |
| Insulin | 41 (72) | 37 (63) |
| Lipid lowering Treatment n (%) | ||
| Statins | 44 (77) | 35 (59) |
| Fibrates | 2 (4) | 7 (12) |
| Antihypertensive treatment n (%) | ||
| ACE inhibitors or ARA II | 51 (88) | 46 (78) |
| 3 or more drugs | 7 (12) | 11 (19) |
| Antiaggregation n (%) | 50 (88) | 53 (90) |
| Actual smokers n (%) | 11 (19) | 11 (19) |
| Inclusion criteria n (%) | ||
| Arterial reconstruction | 27 (47) | 30 (51) |
| Foot ulcer | 16 (28) | 12 (20) |
| ABI < 0.8 | 14 (25) | 17 (29) |
Group A, diabetic patients treated by endocrinology service. Group B, diabetic patients treated by coordinated team, Family Physicians (FP) and endocrinologist, at primary care site.
Data expressed as median (Q1–Q3) or n (%).
ABI, ankle-brachial index. ACE, angiotensin convert enzyme ARA II, angiotensin II-receptor antagonist.